Cantor Fitzgerald Weighs in on JANX FY2026 Earnings

Janux Therapeutics, Inc. (NASDAQ:JANX) – Analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Janux Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings per share of ($4.43) for the year. The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.38) per share.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%.

Several other brokerages also recently commented on JANX. Scotiabank cut their price objective on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a research report on Friday, February 28th. HC Wainwright reissued a “buy” rating and set a $70.00 price objective on shares of Janux Therapeutics in a research report on Monday, March 3rd. Finally, Wedbush reissued an “outperform” rating and set a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $95.25.

Janux Therapeutics Price Performance

Shares of NASDAQ JANX opened at $25.46 on Tuesday. Janux Therapeutics has a 1 year low of $22.48 and a 1 year high of $71.71. The stock has a market cap of $1.51 billion, a P/E ratio of -21.76 and a beta of 2.96. The firm has a 50-day moving average of $26.97 and a 200 day moving average of $37.36.

Insider Activity at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 3,333 shares of the firm’s stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $32.03, for a total transaction of $106,755.99. Following the sale, the insider now owns 82,139 shares of the company’s stock, valued at $2,630,912.17. This trade represents a 3.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 8.10% of the stock is currently owned by insiders.

Institutional Trading of Janux Therapeutics

A number of institutional investors have recently made changes to their positions in JANX. RA Capital Management L.P. boosted its holdings in shares of Janux Therapeutics by 13.1% during the 4th quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company’s stock valued at $554,977,000 after acquiring an additional 1,200,000 shares during the last quarter. Paradigm Biocapital Advisors LP boosted its holdings in shares of Janux Therapeutics by 46.5% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company’s stock valued at $188,246,000 after acquiring an additional 1,115,412 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Janux Therapeutics by 41.2% during the 4th quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company’s stock valued at $190,617,000 after acquiring an additional 1,038,996 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Janux Therapeutics by 47.6% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company’s stock valued at $163,926,000 after acquiring an additional 986,750 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Janux Therapeutics by 596.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,109,978 shares of the company’s stock valued at $59,429,000 after acquiring an additional 950,557 shares during the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.